High intra-uterine exposure to infliximab following maternal anti-TNF treatment during pregnancy

INIS

• levels 100%
• blood 100%
• pregnancy 100%
• antibodies 80%
• patients 60%
• diseases 40%
• children 40%
• inflammation 40%
• newborns 40%
• therapy 20%
• infants 20%
• delivery 20%
• vaccines 20%
• haemophilus 20%
• influenza 20%
• necrosis 20%
• pneumococcus 20%
• placenta 20%

Keyphrases

• Infliximab 100%
• Intrauterine Exposure 100%
• Anti-TNF Treatment 100%
• Treatment during Pregnancy 100%
• Peripheral Blood 30%
• Gestational Week 30%
• Infliximab Levels 30%
• Cord Blood 20%
• Inflammatory Bowel Disease 20%
• During Pregnancy 20%
• Maternal Treatment 10%
• Immune System 10%
• Antibody Response 10%
• Allergic Reaction 10%
• Child Development 10%
• Childhood Vaccination 10%
• 6-month Follow-up 10%
• Pneumococcus 10%
• IgG Antibody 10%
• Placenta 10%
• Vaccine Antibodies 10%
• Vaccine Response 10%
• Haemophilus Influenzae Type b 10%
• Response to Vaccination 10%
• Antibody Titre 10%
• Short-term Complications 10%
• Infliximab Therapy 10%
• Early Postnatal 10%
• Anti-tumor Necrosis Factor Antibody 10%
• Reaction Response 10%
• Last Trimester 10%
• Reproductive Season 10%

Immunology and Microbiology

• Tumor Necrosis Factor 100%
• Infliximab 100%
• Inflammatory Bowel Disease 14%
• Immune System 7%
• Antibody Response 7%
• Antibody Titer 7%
• Immunoglobulin G 7%
• Hypersensitive Response 7%
• Placenta 7%
• Haemophilus Influenzae Type B 7%
• Child Development 7%
• Immunology 7%
• Streptococcus Pneumonia 7%